Literature DB >> 3855280

Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.

W E Fogler, I J Fidler.   

Abstract

The purpose of these studies was to select in vitro tumor cells that were resistant to macrophage-mediated lysis. Seven different heterogeneous murine neoplasms (four fibrosarcomas, a melanoma, a rhabdomyosarcoma, and an osteogenic sarcoma) and one cloned line of a fibrosarcoma were incubated in vitro with syngeneic tumoricidal macrophages. Surviving tumor cells were recovered and expanded to undergo subsequent interaction with tumoricidal macrophages. After six sequential interactions, all cell lines were examined for their susceptibility to lysis mediated by murine peritoneal exudate macrophages activated with liposomes containing muramyl tripeptide phosphatidylethanolamine. In all eight systems, no significant differences were detected between the parent tumor cells and cells that survived the sequential interactions. Neither macrophage infiltration into s.c. tumors nor the experimental or spontaneous metastatic potentials of the parental tumors differed from the lines established by cells surviving macrophage-mediated lysis. Collectively, the data suggest that tumor cell destruction by activated macrophages is nonselective and does not lead to the development of resistant tumor cells nor to cells with altered metastatic properties.

Entities:  

Mesh:

Year:  1985        PMID: 3855280

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Synergistic induction of cytotoxicity in macrophages by murine interferon-gamma and biological response modifiers derived from microorganisms.

Authors:  S Nagao; K Sato; Y Osada
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 2.  Mifamurtide: a review of its use in the treatment of osteosarcoma.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 3.  Macrophage infiltration and tumor progression.

Authors:  S J Normann
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

4.  The systemic activation of macrophages by liposomes containing immunomodulators.

Authors:  R Nayar; I J Fidler
Journal:  Springer Semin Immunopathol       Date:  1985

5.  L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.

Authors:  Kevin Biteau; Romain Guiho; Mathias Chatelais; Julien Taurelle; Julie Chesneau; Nadège Corradini; Dominique Heymann; Françoise Redini
Journal:  Am J Cancer Res       Date:  2016-02-15       Impact factor: 6.166

6.  TNF-alpha mediated selection of macrophage-resistant gene-regulatory tumor variants.

Authors:  L Remels; A Neirynck; L Brys; E Vercauteren; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1989 Sep-Oct       Impact factor: 5.150

Review 7.  Mifamurtide for the treatment of nonmetastatic osteosarcoma.

Authors:  Kosei Ando; Kanji Mori; Nedège Corradini; Françoise Redini; Dominique Heymann
Journal:  Expert Opin Pharmacother       Date:  2011-02       Impact factor: 3.889

Review 8.  Therapy of disseminated melanoma by liposome-activated macrophages.

Authors:  I J Fidler
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

9.  A new 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for testing macrophage cytotoxicity to L1210 and its drug-resistant cell lines in vitro.

Authors:  H Jiao; W Shen; Y Ohe; K Miura; T Tamura; N Saijo
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype.

Authors:  E B Bröcker; G Zwadlo; L Suter; M Brune; C Sorg
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.